title: 3,5,3'-triiodothyroacetic acid therapy for thyroid hormone resistance.
abstract: 3,5,3'-Triiodothyroacetic Acid (Triac) is reputed to suppress pituitary secretion of TSH with minimal metabolic effects. Triac has been used successfully to treat eight patients with thyroid hormone resistance. We gave Triac to a woman with selective pituitary resistance for treatment of hyperthyroidism (patient 1) and to a man with generalized resistance and chronic schizophrenia to determine whether it would improve his schizophrenia (patient 2). Patient 1 was given 0.35-3.5 mg Triac/day; patient 2 was given 0.7-4.2 mg/day. Dosages were increased by 0.7 mg/day every 2 weeks. Serum T3, T4, free T4, TSH, TSH response to TRH, systolic time intervals (STI), angiotensin-converting enzyme (ACE), and lipids were monitored bimonthly. In both patients, there was no change in symptoms, weight, lipids, or STI. In patient 1, basal TSH suppressed from 16.3 to 1.5 mU/L; in patient 2, from 2.0 to 0.5 mU/L. The peak TSH response to TRH stimulation decreased from 144 to 12.5 mU/L in patient 1 and from 14.2 to 2.8 mU/L in patient 2. Serum T4 decreased from 160 to 109 nmol/L in patient 1 and from 270 to 192 nmol/L in patient 2. ACE levels were persistently elevated in both patients. Resting energy expenditure, measured by oxygen consumption, was increased by Triac in both patients (12% in patient 1 and 9% in patient 2). Although Triac suppressed TSH and T4 secretion in both patients, it did not reduce peripheral action of thyroid hormone as expressed in STI, resting energy expenditure, and ACE. We conclude that in these two patients with resistance to thyroid hormone, at the doses used to suppress TSH and T4 secretion, the intrinsic peripheral action of Triac offset whatever decrease in thyroid hormone secretion it produced.
authors.affiliation: Wadsworth Veterans Administration Medical Center, University of California, Los Angeles 90073.
authors.forename: J M
authors.initials: JM
authors.lastname: Kunitake
authors.forename: N
authors.initials: N
authors.lastname: Hartman
authors.forename: L C
authors.initials: LC
authors.lastname: Henson
authors.forename: J
authors.initials: J
authors.lastname: Lieberman
authors.forename: D E
authors.initials: DE
authors.lastname: Williams
authors.forename: M
authors.initials: M
authors.lastname: Wong
authors.forename: J M
authors.initials: JM
authors.lastname: Hershman
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy* / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008297:Male; D010902:Pituitary Gland / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy; D013963:Thyroid Hormones / Q000097:blood*; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism; D014284:Triiodothyronine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D008055:Lipids; D013963:Thyroid Hormones; D014284:Triiodothyronine; C010642:3,3',5-triiodothyroacetic acid; D013972:Thyrotropin